Trump will sign FDA user fee reau­tho­riza­tion bill, end­ing threat of agency lay­offs

Ahead of its sum­mer re­cess, the US Sen­ate to­day fol­lowed its House coun­ter­parts and passed a bi­par­ti­san bill to reau­tho­rize FDA user fee pro­grams for pre­scrip­tion drugs, gener­ic drugs, med­ical de­vices and biosim­i­lars for the next five years. A spokesman for Pres­i­dent Don­ald Trump told Fo­cus, “The Pres­i­dent will sign this bill, but we look for­ward to work­ing with Con­gress to ad­dress fur­ther ne­go­ti­a­tions.”

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN